Skip to main navigation Skip to search Skip to main content

Does clozapine treat antipsychotic-induced behavioural supersensitivity through glutamate modulation within the striatum?

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

Behavioural supersensitivity may be a result of increased glutamate sensitivity of D2-MSN and reduced sensitivity to dopamine. We propose that clozapine may address behavioural supersensitivity by modulating glutamate activity which may partially explain its unique effectiveness in the setting of treatment resistant schizophrenia.
Original languageEnglish
Pages (from-to)1839-1842
Number of pages4
JournalMolecular Psychiatry
Volume28
Issue number5
DOIs
Publication statusPublished - May 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being
  • ARC Industrial Transformation Training Centre for Cryo-Electron Microscopy of Membrane Proteins for Drug Discovery

    Sexton, P. (Primary Chief Investigator (PCI)), Rouiller, I. (Chief Investigator (CI)), Wootten, D. (Chief Investigator (CI)), van Oijen, A. (Chief Investigator (CI)), Parker, M. W. (Chief Investigator (CI)), Lucet, I. (Partner Investigator (PI)), Griffin, M. D. W. (Chief Investigator (CI)), Adams, D. J. (Chief Investigator (CI)), Czabotar, P. E. (Partner Investigator (PI)), Flocco, M. (Partner Investigator (PI)), Shepherd, R. K. (Partner Investigator (PI)), Ciferri, C. (Partner Investigator (PI)), Williams, P. A. (Partner Investigator (PI)), Brown, D. (Partner Investigator (PI)), Schreuder, H. (Partner Investigator (PI)), Reedtz-Runge, S. (Partner Investigator (PI)), Drinkwater, C. (Partner Investigator (PI)), Howard, B. L. (Partner Investigator (PI)), Betigeri, G. (Partner Investigator (PI)), Pryor, E. (Partner Investigator (PI)), How, J. (Project Manager), Pierce, T. (Project Manager), Lees, J. (Partner Investigator (PI)) & How, J. (Project Manager)

    Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom)

    23/03/2123/03/27

    Project: Research

Cite this